Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Satisfaction with Medication"'
Publikováno v:
International Journal of Pharmaceutical and Healthcare Marketing, 2018, Vol. 12, Issue 4, pp. 409-432.
Externí odkaz:
http://www.emeraldinsight.com/doi/10.1108/IJPHM-10-2016-0053
Publikováno v:
Patient Preference and Adherence, Vol Volume 12, Pp 1203-1211 (2018)
Saul Alcaraz,1 Carme Viladrich,2 Joan Trujols,1,3 Núria Siñol,1 José Pérez de los Cobos1,3,4 1Addictive Behaviors Unit, Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelo
Externí odkaz:
https://doaj.org/article/f4d86cf72ec747c7a7bb8fa80cf1cc3a
Publikováno v:
Tropical Journal of Pharmaceutical Research; Vol. 22 No. 2 (2023); 439-446
Purpose: To determine satisfaction with treatment and adherence to medication amongst Chinese patients with rheumatoid arthritis. Methods: This cross-sectional study enrolled 398 rheumatoid arthritis (RA) patients who filled out questionnaire during
To systematically review the relevant studies and scales of satisfaction with medication in children (TS-M), and to provide a reference for the evidence-based development of TS-M scales for children.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8353f80c4c796386cbc15fceeb80ebe
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Roumen Milev, Can-Bind Investigator Team, Wendy Lou, Sagar V. Parikh, Trisha Chakrabarty, Benicio N. Frey, Sidney H. Kennedy, Emma Morton, Daniel J. Müller, Erin E. Michalak, Shane McInerney, Peter Giacobbe, Raymond W. Lam, Susan Rotzinger, Venkat Bhat
Publikováno v:
CNS Drugs. 35:439-450
Non-response to first-line treatment for major depressive disorder (MDD) is common; for such individuals, quality of life (QoL) impairments can be severe. Identifying predictors of QoL changes may support the management of cases with persistent depre
Autor:
Mirjam C. Hegeman, Jolanda A. Schoemaker-Delsing, Jacqueline T. M. Luttikholt, Harald E. Vonkeman
Publikováno v:
Rheumatology International
Rheumatology international, 41(5), 973-979. Springer
Rheumatology international, 41(5), 973-979. Springer
Rheumatoid arthritis (RA) patients often report lacking information on medication side effects. The aims of this study were to observe how rheumatology healthcare providers deliver medication information and to determine in which specific domains inf
Autor:
Sarah Raifman, S Kaller, Mitchell D. Creinin, Tina Raine-Bennett, M. Antonia Biggs, Erin Berry, Elizabeth Micks, C. Finley Baba, Daniel Grossman, Tanvi Gurazada, Karen R. Meckstroth, Sarah Averbach, Sally Rafie
Publikováno v:
Obstetrics and Gynecology
Obstetrics and gynecology, vol 137, iss 4
Obstetrics and gynecology, vol 137, iss 4
Medication abortion with pharmacist-dispensed mifepristone is effective, with a low prevalence of adverse events, and patients are satisfied with the model of care.
OBJECTIVE: To estimate effectiveness and acceptability of medication abortion wi
OBJECTIVE: To estimate effectiveness and acceptability of medication abortion wi
Autor:
Orellana Pérez, Mariona
El Trastorno por Déficit de Atención e Hiperactividad es un trastorno del neurodesarrollo muy común en la infancia y en la adolescencia. Se caracteriza por un déficit en el control atencional y/o hiperactividad/impulsividad que interfiere negativ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4854::c6d8a234e962a3897affe025dc49cd85
http://hdl.handle.net/20.500.12328/3399
http://hdl.handle.net/20.500.12328/3399
Autor:
P. Bresser, Merel Kimman, Catharina C. Moor, Joachim G.J.V. Aerts, Jan C. Grutters, Marlies S. Wijsenbeek, Rémy L M Mostard, Carmen D. Dirksen
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-7 (2020)
Respiratory Research, 21(1):196. BioMed Central Ltd
Respiratory Research, 21(1):196. BioMed Central Ltd.
Respiratory Research
Respiratory Research, 21(1):196. BioMed Central Ltd
Respiratory Research, 21(1):196. BioMed Central Ltd.
Respiratory Research
Background Two antifibrotic drugs, nintedanib and pirfenidone, are available for treatment of idiopathic pulmonary fibrosis (IPF). Although efficacy and adverse events have been well studied, little is known about patient experiences with these drugs